Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Total revenues	$ 213	$ 15	$ 297	$ 54
Costs and expenses:
Production costs	218	290	488	558
Research and development	1,106	900	2,497	1,902
General and administrative	1,619	1,639	3,283	4,087
Total costs and expenses	2,943	2,829	6,268	6,547
Operating loss	(2,730)	(2,814)	(5,971)	(6,493)
Interest expense and other finance costs	(19)		(19)
Interest and other income/expense	21	55	47	116
Redeemable warrants valuation adjustment	529		923
Insurance proceeds from legal settlement, net		1,436		1,436
Gain (Loss) on sales of short term marketable securities	6	20	6	(87)
Gain from sale of income tax net operating losses and research credits				1,561
Net loss	(2,193)	(1,303)	(5,014)	(3,467)
Other comprehensive income (loss):
Reclassification adjustments for loss on sales of short term marketable securities included in net loss	(6)		(6)	87
Unrealized gain on marketable securities	18	38	29	97
Net comprehensive loss	$ (2,181)	$ (1,265)	$ (4,917)	$ (3,283)
Basic and diluted loss per share	$ (0.08)	$ (0.06)	$ (0.19)	$ (0.16)
Weighted average shares outstanding, basic and diluted	27,306,321	20,667,343	26,329,123	20,648,836
US [Member]
Revenues:
Clinical treatment programs	$ 74	$ 15	$ 97	$ 54
Europe [Member]
Revenues:
Clinical treatment programs	$ 139		$ 200